| <p>Jagsonpal Pharmaceuticals Ltd. announced a Business Transfer Agreement with Group Pharmaceuticals Limited for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The initial consideration for the acquisition is Rs 23.7 crores, with an additional consideration potentially reaching up to Rs 23.0 crores linked to FY 2027-28 sales, capped at a total of Rs 46.7 crores. The transaction, expected to close on or before November 1, 2026, will strengthen Jagsonpal’s pharmaceutical portfolio and expand its presence in women’s healthcare, according to a company statement.</p> |